Fidelity Investments
FENC icon

Fidelity Investments’s Fennec Pharmaceuticals FENC Stock Holding History

Fidelity Investments’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.2K Buy
4,254
+1,831
+76% +$14.1K ﹤0.01% 4409
2025
Q4 		$18.7K Sell
2,423
-301
-11% -$2.47K ﹤0.01% 4490
2025
Q3 		$25.5K Buy
2,724
+343
+14% +$2.97K ﹤0.01% 4263
2025
Q2 		$19.8K Buy
2,381
+540
+29% +$3.69K ﹤0.01% 4287
2025
Q1 		$11.2K Sell
1,841
-199
-10% -$1.28K ﹤0.01% 4458
2024
Q4 		$12.9K Buy
2,040
+857
+72% +$4.39K ﹤0.01% 4366
2024
Q3 		$5.92K Buy
1,183
+41
+4% +$237 ﹤0.01% 4581
2024
Q2 		$6.98K Sell
1,142
-3,911
-77% -$32.5K ﹤0.01% 4448
2024
Q1 		$56.2K Buy
5,053
+24
+0.5% +$241 ﹤0.01% 3528
2023
Q4 		$56.4K Buy
5,029
+4,607
+1,092% +$38.2K ﹤0.01% 3466
2023
Q3 		$3.17K Buy
422
+291
+222% +$2.37K ﹤0.01% 4435
2023
Q2 		$1.16K Buy
131
+19
+17% +$158 ﹤0.01% 4687
2023
Q1 		$932 Hold
112
– – ﹤0.01% 4745
2022
Q4 		$1.07K Hold
112
– – ﹤0.01% 4637
2022
Q3 		$1K Hold
112
– – ﹤0.01% 4662
2022
Q2 		$1K Hold
112
– – ﹤0.01% 4709
2022
Q1 		$1K Buy
+112
New +$564 ﹤0.01% 4786

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Fidelity Investments's FENC Position: Q1 2026 in Review

Fidelity Investments increased its Fennec Pharmaceuticals (FENC) stake by 76% in Q1 2026, buying an estimated $14.1K and bringing the position to 4,254 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4409.

Fidelity Investments first reported a position in FENC in Q1 2022 and has held it in 17 quarters since. The position peaked at $56.4K in Q4 2023. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Fidelity Investments held 4,254 shares of Fennec Pharmaceuticals worth $26.2K as of Q1 2026.
  • Fidelity Investments bought 1,831 Fennec Pharmaceuticals shares in Q1 2026, an estimated $14.1K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4409 holding.
  • Fidelity Investments first reported a position in Fennec Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Fidelity Investments's Fennec Pharmaceuticals position peaked at $56.4K in Q4 2023.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.